logo-loader

IBC Advanced Alloys appoints Alastair Neill to help with mineral projects

Last updated: 14:02 14 Nov 2011 EST, First published: 15:02 14 Nov 2011 EST

no_picture_pai

Rare metals maker IBC Advanced Alloys (CVE:IB) appoints Alastair Neill to its board to help guide the development of upstream mineral projects and processing sites, the company said Monday.

Neill, who began on November 1, replaces Denis Brady on the board of directors. Neill is a former vice president of sales and general manager of rare earth division for Neo Material Technologies (TSE:NEM).

He holds over 15 years worth of direct rare earth elements experience with downstream end-users in Korea, Japan, Europe and North America. 

Currently, Neill is executive vice president of Dacha Strategic Metals and serves on the advisory board of Rare Earth Element World – an international organization that provides industry leadership in the rare earths, rare metals and critical metals sector.

In a statement, IBC chief executive, Anthony Dutton, said: "Alastair is an acknowledged international rare earths and rare metals expert, and has an impressive history of business and technical expertise and success.

"We believe IBC will benefit tremendously from Alastair’s deep market knowledge and industry experience.  We look forward to his guidance and leadership as IBC continues its growth and develops its business strategy in North America and abroad."

IBC Advanced Alloys, formerly known as International Beryllium Corporation, makes and develops beryllium copper, chrome zirconium copper, chromium copper alloys, nickel aluminum bronze, and other alloys of copper.

IBC’s rare metal alloys are used in a number of industries, including nuclear energy, automotive, telecommunications and a range of industrial applications.

It has production facilities in Indiana, Massachusetts, Pennsylvania and Missouri. The company also owns prospective beryllium properties in the Western U.S. covering about 9,500 hectares.

The Vancouver-based company’s stock rose 1.29 percent to 16 cents a share Monday on the junior venture exchange.

BenevolentAI advances novel ulcerative colitis treatment through Phase 1a trial

BenevolentAI (OTC:BAIVF) chief scientific officer Dr Anne Phelan joins Proactive's Stephen Gunnion with positive safety data from the Phase 1a, first-in-human, clinical study of BEN-8744 in healthy volunteers. Phelan explained that BEN-8744 is a potent, selective PD10 inhibitor, uniquely...

1 hour, 51 minutes ago